Co-hosted by the European Association for Cancer Research and AstraZeneca

With world leading expert speakers, we will present and discuss the current clinical utilities of ctDNA and cfDNA based liquid biopsies (with examples in breast, lung, colorectal and bladder cancers); we will review the opportunities and challenges of cancer early detection with minimally invasive approaches and scan the near and far horizon for next generation technologies for liquid biopsy.

Attendees will gain a holistic understanding of circulating nucleic acids, how they are built into clinical trial designs to inform patient management, the multiple measurements possible to gain the most information from a blood sample and the direction of travel for this exciting field.   

Topics to be covered:

• Horizons for liquid biopsy
• Interventional ctDNA in clinical trials
• Early detection using liquid biopsy

More information and to register

Abstract submission deadline: 18 November 2024